Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310478 | 0.92 | BRD4 (0.32) | BRD4BRPF1BRD9 | |
| SCHEMBL24310089 | 0.89 | DRD2 (0.35) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL24310049 | 0.89 | PAK1 (0.36) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL24310065 | 0.88 | DRD2 (0.37) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL24309479 | 0.87 | HTR1A (0.33) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL24309536 | 0.87 | BRPF1 (0.34) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL24310513 | 0.86 | MEN1 (0.33) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL24310771 | 0.85 | HTR1A (0.36) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL29567079 | 0.85 | HTR1A (0.36) | HTR1ADRD2DRD4HTR2AHTR2C | |
| SCHEMBL24309806 | 0.84 | EGFR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |